New Retail of Pharmaceuticals
Tags
Summary
At the same time, the shift of medical services and patient drug-purchasing behavior online, innovative payment models, and a capital-driven digital health ecosystem are disrupting traditional models of care and medicine purchasing.
How should pharmaceutical retailers view the changes unfolding in their industry? How can they define their own position amid these changes? On the latter question, this book offers no answers—that is a strategic choice for seasoned operators, grounded in their understanding of industry change and awareness of their own strengths and weaknesses. On the former, the book delivers: it reveals the underlying logic of pharmaceutical retail evolution at home and abroad behind the changes of new pharmaceutical retail.
Editor's review
Who it's for
A good fit for
- Executives and store managers of pharmaceutical retail companies
- Professionals in digital health and online pharmacy
- Analysts focused on healthcare payment and industry investment
- Upper-level students in pharmacy and public health
Not a good fit for
- Readers seeking ready-to-copy transformation plans and operational templates
- Beginners with no background in pharmacy or retail
- Medical professionals concerned only with clinical practice
Reading tips
- Start with the chapters on the essence of pharmaceutical retail evolution to build an analytical framework.
- Relate the reading to your company's current situation and list questions to verify as you go.
- Focus on the sections on online migration and payment change, comparing them with local market conditions.
- After finishing, summarize your own strengths and weaknesses in one page as a starting point for action.
About the publisher
The Publishing House of Electronics Industry is a comprehensive publisher distinguished by its focus on electronic information and related fields. Judging from the more than 3,000 titles in its catalogue, its publishing covers programming and design, artificial intelligence, computer science, finance and economics, photography, and social sciences, attending both to cutting-edge technology and to general readers. Representative titles include Factor Investing: Methods and Practice, x86 Assembly Language: From Real Mode to Protected Mode, The RISC-V Reader, Artificial Intelligence: Speech Recognition, Understanding and Practice, Phased Array Radar Technology, Radar Target Characteristics, and 100 Go Mistakes and How to Avoid Them, most of which centre on technical methods and engineering practice. Its authors include Shi Chuan, Li Zhong, Wang Xiaobo, David Patterson, Andrew Waterman, and Yu Zihao, among others from China and abroad. Owing to limited public information, no further publishing features are elaborated here.
Contents
- 版权信息
- 内容简介
- 推荐序一 零售没有新旧，只有不断迭代
- 推荐序二 医药新零售，东风已来
- 自序
- 第1章 漫谈新零售
- 1.1 张仲景大药房和支付宝开出了“未来药店”
- 1.2 新零售起源
- 1.3 腾讯智慧零售布局
- 1.4 新零售物种大爆发
- 1.5 新零售的本质
- 第2章 传统医药零售市场
- 2.1 我国医药零售行业所经历的历史阶段
- 2.2 我国当下的主要医药零售业态
- 2.3 解码四大上市公司
- 2.4 单体药店出路在何方
- 2.5 传统零售的挑战
- 第3章 医药电商二十年
- 3.1 医药电商二十年发展历程
- 3.2 医药电商市场格局初步形成
- 3.3 医药电商赚钱吗
- 3.4 向上的力量：医药电商的驱动因素
- 3.5 向下的拉扯：医药电商的发展困局
- 第4章 医药零售市场政策脉络
- 4.1 宏观政策法规脉络梳理
- 4.2 《中华人民共和国药品管理法》
- 4.3 《药品经营质量管理规范》
- 4.4 药诊所相关政策
- 4.5 药店电子处方与远程审方
- 第5章 资本纵横医药零售
- 5.1 资本扩张是主旋律：且谈四大上市公司的扩张策略
- 5.2 并购新兴药房：国内最大药店收购案
- 5.3 高瓴资本：横空出世的“医药零售之王”
- 5.4 国大药房：两年新增10000家门店的版图
- 5.5 老百姓：破百亿元的背后
- 5.6 河北神威药业与天士力集团：工业企业涉足医药新零售
- 5.7 收购药店如何估值
- 5.8 新增门店带来的增长需要打折吗
- 第6章 新零售时代的创新业态
- 6.1 “网红”分子药局
- 6.2 润天智慧药店：科技赋能、店仓合一
- 6.3 万芸健康药房：贯彻“药店生态位”
- 第7章 新零售时代的新流量逻辑
- 7.1 药诊所：“流量”与“留量”
- 7.2 平安万家折戟药诊所的启示
- 7.3 电子处方对于药店的流量价值
- 7.4 京东到家、饿了么、美团等O2O平台如何创造新流量
- 7.5 商业保险创造新流量
- 7.6 院边店的巨大流量价值
- 第8章 自有品牌：新零售时代药店品类发展的必然逻辑
- 8.1 自有品牌：零售企业必经之路
- 8.2 亚马逊自有品牌策略
- 8.3 沃博联自有品牌
- 8.4 我国药店自有品牌
- 第9章 重构供应链
- 9.1 政策重塑流通格局，供应链重组势在必行
- 9.2 互联网重构药品供应链
- 9.3 大数据驱动商品选品逻辑重塑
- 9.4 供应链重组中的金融创新机会
- 第10章 科技赋能医药新零售
- 10.1 SaaS如何赋能新零售
- 10.2 人工智能嫁接新零售
- 10.3 思考：还有哪些服务能够延展至零售药店场景
- 第11章 CVS：迅速崛起的并购之王
- 11.1 CVS成长史
- 11.2 CVS转型的“三驾马车”
- 11.3 CVS的药店生态圈
- 11.4 对国内企业的启示
- 第12章 沃博联：自我驱动的连锁巨头
- 12.1 沃博联成长史
- 12.2 批零一体化战略对中国的启示
- 12.3 极其成功的自有品牌战略
- 12.4 业内首创的多元化经营方式
- 12.5 线上线下一体化的全渠道业务布局
- 12.6 沃博联与中国
FAQ
Does this book provide concrete implementation plans for new pharmaceutical retail?
Why is pharmaceutical retail described as resilient?
What industry changes does the book cover?
Comments
Find this book
This site is an index: you start “Search all sources” in your browser, and the entries it lists all point to third-party sites; please judge their availability yourself.
About the author
Public information about Wang Hao is limited, and only a general picture can be drawn from the works published under this name. The collection contains fourteen of his works, spanning medicine, architecture, industrial technology, finance, health, and examinations, and covering such areas as cardiac ultrasound, the clinical experience of a renowned traditional Chinese medicine practitioner, ecological strategy, coal-seam mining-induced fracturing and gas flow, energy economics, health knowledge, a Mongolian language textbook, and workplace safety regulations. His writings are therefore not confined to a single specialty but combine academic and practical concerns, encompassing both technical discussions for professional readers and popular works for a general audience. The works are characterized by the integration of materials and the organization of experience, with plain language and clear structure that make them suitable for readers of varied backgrounds.
Liu Xiaodong is an author whose publicly available information is limited; what can be confirmed is that he writes on management with a focus on the pharmaceutical retail sector. His representative work is New Retail in Pharmaceuticals, which is classified under management and is the only title by him in this collection. The subject places him at the intersection of the pharmaceutical industry and retail models, discussing how pharmaceutical distribution and sales are being adjusted in the context of new retail. This is management writing aimed at industry practice, typically taking industry change as its starting point and examining the relationship between channels, business models, and operational approaches for practitioners and management readers interested in the field. Since no reliable public information is available about his nationality, dates of birth and death, education, or professional career, further speculation about his personal background is inappropriate. On the basis of the available material, an understanding of Liu Xiaodong's writing should rest mainly on the industry observations and management perspective presented in New Retail in Pharmaceuticals.
